Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 1669 clinical trials
Featured trial
CardioMEMSTM HF System Post Approval Study

CardioMEMSTM HF System Post Approval Study

  • 522 views
  • 23 Nov, 2020
  • 1 location
A Study of Rodatristat Ethyl in Patients With Pulmonary Arterial Hypertension (ELEVATE 2)

The purpose of this study is to assess the safety and efficacy of Rodatristat Ethyl in pulmonary arterial hypertension (PAH) patients.

  • 31 views
  • 04 Oct, 2022
  • 55 locations
A Phase 2b, Randomized, Double-Blind, Multicenter, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Treprostinil Palmitil Inhalation Powder in Participants With Pulmonary Arterial Hypertension

The main objective of the study is to assess the effect of treprostinil palmitil inhalation powder (TPIP) compared with placebo on pulmonary vascular resistance.

  • 5 views
  • 17 Oct, 2022
  • 45 locations
An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)

This open-label extension study will evaluate the long-term effects of GB002 (seralutinib) in subjects who previously participated in a GB002 PAH study.

  • 0 views
  • 22 Oct, 2022
  • 28 locations
A Prospective, Multicenter, Single-Arm, Open-Label, Phase 4 Study of the Effects of Selexipag on Right Ventricular Remodeling in Pulmonary Arterial Hypertension Assessed by Cardiac Magnetic Resonance Imaging (RESTORE)

The purpose of the study is to assess the effects of selexipag on right ventricular (RV) function in participants with Pulmonary arterial hypertension (PAH).

  • 0 views
  • 24 Oct, 2022
  • 29 locations
  • 301 views
  • 20 Oct, 2022
  • 73 locations
A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Sotatercept When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients (HYPERION)

The objective of this study is to evaluate the effects of sotatercept treatment (plus background PAH therapy) versus placebo (plus background PAH therapy) on time to clinical worsening (TTCW) in participants who are newly diagnosed with PAH and are at intermediate or high risk of disease progression.

  • 0 views
  • 27 Oct, 2022
  • 92 locations
REACH- Reducing Risk With E-based Support for Adherence to Lifestyle Change in Hypertension

blood pressure and lifestyle adherence among subjects diagnosed with Stage 1 or 2 hypertension. Primary hypotheses. 1. e-Counseling (vs. Control) will significantly reduce SBP, DBP

stroke
  • 259 views
  • 07 Nov, 2020
  • 3 locations
  • 0 views
  • 22 Oct, 2022
  • 27 locations
  • 390 views
  • 23 Oct, 2022
  • 181 locations